Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia
Alessandra Ferrajoli(The University of Texas MD Anderson Cancer Center), George A. Călin(The University of Texas MD Anderson Cancer Center), Laura Z. Rassenti(University of California San Diego), Mariko Ikuo(The University of Texas MD Anderson Cancer Center), M. James You, Michael J. Keating(The University of Texas MD Anderson Cancer Center), Tait D. Shanafelt(Mayo Clinic), Susan Lerner(Molecular Templates (United States)), Thomas J. Kipps(University of California San Diego), James M. Reuben(The University of Texas MD Anderson Cancer Center), Masayoshi Shimizu(The University of Texas MD Anderson Cancer Center), Nazila Nouraee(The University of Texas MD Anderson Cancer Center), Lianchun Xiao(The University of Texas MD Anderson Cancer Center), Steliana Calin(The University of Texas MD Anderson Cancer Center), Kari G. Rabe(Mayo Clinic), Asish K. Ghosh(University of Chicago), Cristina Ivan(The University of Texas MD Anderson Cancer Center), Zeev Estrov(The University of Texas MD Anderson Cancer Center), Jianhua Hu(The University of Texas MD Anderson Cancer Center), John T. Manning(The University of Texas Medical Branch at Galveston), Neil E. Kay(Mayo Clinic), William G. Wierda(The University of Texas MD Anderson Cancer Center), Susan O’Brien(University of California, Irvine)
Cited by 220
Related Papers
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
|Blood|2018|1.7k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k